Sejmet Pharmaceuticals

Sejmet Pharmaceuticals is a San Diego-based biotechnology company focused on developing next-generation small molecule inhibitors for the treatment of cancer. The company specializes in targeting the DNA damage response (DDR) pathway, with a particular emphasis on Ubiquitin-Specific Protease 1 (USP1). Sejmet's lead program aims to treat patients with BRCA-deficient and other homologous recombination-deficient (HRD) tumors, potentially offering a synergistic approach when combined with PARP inhibitors. The company is currently progressing its lead candidates through preclinical studies to support future Investigational New Drug (IND) filings. Sejmet was founded by industry veterans with extensive experience in drug discovery and development.